Concurrent urologic and palliative care after cystectomy for treatment of muscle-invasive bladder cancer

被引:11
|
作者
Rabow, Michael W. [1 ]
Benner, Carly [1 ]
Shepard, Nancy [2 ]
Meng, Maxwell V. [3 ]
机构
[1] UCSF, Dept Med, San Francisco, CA USA
[2] UCSF, Helen Diller Family Comprehens Canc Ctr, Dept Nursing, San Francisco, CA USA
[3] UCSF, Dept Urol, San Francisco, CA USA
关键词
Cystectomy; Bladder cancer; Symptoms; Distress; Palliative care; QUALITY-OF-LIFE; RADICAL CYSTECTOMY; VALIDATION; SYMPTOMS; DISTRESS; BURDEN; IMPACT; SCALE;
D O I
10.1016/j.urolonc.2015.02.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To characterize the effect of palliative care provided concurrently with usual urologic care for patients with bladder cancer undergoing cystectomy. Materials and methods: Prospective, 6-month, serial cohort study comparing 33 participants receiving usual care with cystectomy for muscle-invasive bladder cancer, with 30 participants also receiving concurrent palliative care. Patients and family caregivers completed validated symptom assessment and satisfaction surveys preoperatively and at 2, 4, and 6 months postoperatively. Results: The intervention group saw improvements in most symptom measures over the 6 months following cystectomy compared with the control group. Depression and anxiety decreased over the 6-month period for the intervention group patients but increased over this time among the controls (P = 0.01). Fatigue decreased to a minimum for the intervention group participants at 4 months, whereas it peaked at this time for control participants (0.002). Quality-of-life and posttraumatic growth scores followed a similar pattern, with scores peaking at 4 months for the intervention group whereas controls reported their lowest scores at this time (P = 0.01 and P = 0.03, respectively). Changes in pain scores did not reach statistical significance. Neither family caregiver burden nor patient satisfaction showed statistically significant changes over time. Conclusions: Patients who received concurrent palliative care in addition to usual urologic care following radical cystectomy for muscle invasive bladder cancer had better outcomes, including improved fatigue, depression, quality of life, and posttraumatic growth. Although further research on this topic is needed, our results suggest that providing palliative care services in addition to usual urologic care for patients with bladder cancer may significantly reduce postoperative symptoms. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:267.e23 / 267.e29
页数:7
相关论文
共 50 条
  • [31] Treatment of muscle-invasive bladder cancer: A systematic review
    Chou, Roger
    Selph, Shelley S.
    Buckley, David I.
    Gustafson, Katie S.
    Griffin, Jessica C.
    Grusing, Sara E.
    Gore, John L.
    CANCER, 2016, 122 (06) : 842 - 851
  • [32] Managing muscle-invasive bladder cancer in the elderly
    Weizer, Alon Z.
    Palella, Gaetano V.
    Montgomery, Jeffrey S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 903 - 915
  • [33] Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
    Stenzl, Arnulf
    Cowan, Nigel C.
    De Santis, Maria
    Kuczyk, Markus A.
    Merseburger, Axel S.
    Jose Ribal, Maria
    Sherif, Amir
    Witjes, J. Alfred
    EUROPEAN UROLOGY, 2011, 59 (06) : 1009 - 1018
  • [34] Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium
    Mir, Maria Carmen
    Marchioni, Michele
    Zargar, Homi
    Zargar-Shoshtari, K.
    Fairey, A. S.
    Mertens, Laura S.
    Dinney, C. P.
    Krabbe, L. M.
    Cookson, M. S.
    Jacobsen, N. E.
    Griffin, J.
    Montgomery, J. S.
    Vasdev, N.
    Yu, E. Y.
    Xylinas, E.
    McGrath, J. S.
    Kassouf, W.
    Dall'Era, M. A.
    Sridhar, S. S.
    Aning, J.
    Shariat, S. F.
    Wright, J. L.
    Thorpe, A. C.
    Morgan, T. M.
    Holzbeierlein, J. M.
    Bivalacqua, T. J.
    North, S.
    Barocas, D. A.
    Lotan, Y.
    Grivas, P.
    Stephenson, A. J.
    Shah, J. B.
    van Rhijn, B. W.
    Spiess, P. E.
    Daneshmand, D.
    Black, P. C.
    EUROPEAN UROLOGY FOCUS, 2021, 7 (06): : 1347 - 1354
  • [35] Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
    Stenzl, A.
    Cowan, N. C.
    De Santis, M.
    Kuczyk, M. A.
    Merseburger, A. S.
    Ribal, M. J.
    Sherif, A.
    Witjes, J. A.
    ACTAS UROLOGICAS ESPANOLAS, 2012, 36 (08): : 449 - 460
  • [36] Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer
    Desai, Avani
    Bouknight, Lucas
    Reed, Thomas
    Mueller, Dana
    Osterman, Chelsea
    Repka, Michael
    Rose, Tracy
    Smith, Angela B.
    BLADDER CANCER, 2024, 10 (02) : 145 - 155
  • [37] Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
    Elsayed, Dalia Hamouda
    Elfarargy, Ola M.
    Elderey, Mohamed Salah
    Mandour, Doaa
    Atef, Nora
    Hemeda, Rehab
    Kamel, Mostafa
    Azony, Ahmed
    Taha, Heba F.
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2023, 27 (01): : 1 - 9
  • [38] Adjuvant Radiotherapy Use by US Radiation Oncologists After Radical Cystectomy for Muscle-invasive Bladder Cancer
    Solanki, A. A.
    Martin, B.
    Korpics, M.
    Small, C.
    Harkenrider, M. M.
    Mitin, T.
    CLINICAL ONCOLOGY, 2017, 29 (07) : 429 - 435
  • [39] Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
    Peyrottes, Arthur
    Ouzaid, Idir
    Califano, Gianluigi
    Hermieu, Jean-Francois
    Xylinas, Evanguelos
    MEDICINA-LITHUANIA, 2021, 57 (08):
  • [40] Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?
    Kuczyk, M
    Turkeri, L
    Hammerer, P
    Ravery, V
    EUROPEAN UROLOGY, 2003, 44 (01) : 57 - 64